pyrroles has been researched along with lansoprazole in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (61.76) | 24.3611 |
| 2020's | 13 (38.24) | 2.80 |
| Authors | Studies |
|---|---|
| Arikawa, Y; Hirase, K; Hori, Y; Imanishi, A; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H; Tsukimi, Y | 1 |
| Hori, Y; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H | 1 |
| Hori, Y; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H; Takeuchi, T | 1 |
| Ashida, K; Chiba, T; Hiramatsu, N; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E | 1 |
| Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E | 2 |
| Asaka, M; Funao, N; Murakami, K; Nishimura, A; Sakurai, Y; Shiino, M | 1 |
| Gotoda, T; Iwatsuka, K; Kusano, C; Moriyama, M; Suzuki, S | 1 |
| Mizukami, K; Murakami, K | 1 |
| Miwa, H; Mori, Y; Nishimura, A; Sakaki, N; Sakurai, Y; Takanami, Y; Tatsumi, T; Uedo, N; Watari, J | 1 |
| Arai, E; Fukui, H; Fukui, S; Kondo, T; Kono, T; Miwa, H; Ohda, Y; Okugawa, T; Oshima, T; Taki, M; Takimoto, M; Tomita, T; Tozawa, K; Watari, J; Yamasaki, T | 1 |
| Fujisawa, T; Horiuchi, A; Imai, R; Kimura, T; Kiyosawa, K; Kubota, D; Maruyama, M; Matsuda, Y; Miyajima, M; Mori, H; Tanaka, N; Tokutake, K; Wada, S | 1 |
| Ashida, K; Funao, N; Kawai, T; Mizokami, Y; Nishimura, A; Oda, K; Soen, S; Sugano, K | 1 |
| Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K | 1 |
| Fushimi, S; Horikawa, Y; Kato, Y; Mimori, N; Mizutamari, H; Okubo, S; Sato, S | 1 |
| Harada, S; Higuchi, K; Hirai, A; Kawaguchi, S; Kojima, Y; Ota, K; Takahashi, Y; Takeuchi, T; Tokioka, S; Tominaga, K | 1 |
| Akasaka, T; Arao, M; Fukui, K; Hamada, K; Hanaoka, N; Higashino, K; Iishi, H; Ishihara, R; Iwatsubo, T; Kanesaka, T; Kato, M; Matsuura, N; Nakahira, H; Okada, H; Shichijo, S; Shimokawa, T; Suzuki, S; Takeuchi, Y; Tonai, Y; Uedo, N; Yamamoto, S; Yamasaki, Y | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J | 1 |
| Hatakeyama, H; Noguchi, Y; Seko, T; Tachi, T; Teramachi, H | 1 |
| Habu, Y | 1 |
| Chen, M; Chong, CF; Chun, HJ; Dai, N; Fei, G; Funao, N; Goh, KL; Sheu, BS; Xiao, Y; Zhang, S; Zhou, W | 1 |
| Asahina, A; Kikuchi, S; Nobeyama, Y; Saeki, H | 1 |
| Hongo, M; Hunt, RH; Lazarescu, A; Lottrup, C; Scarpignato, C; Stein, E; Wu, JCY | 1 |
| Fujiki, S; Gotoda, T; Ishiguro, M; Kawai, D; Kono, Y; Okanoue, S; Takemoto, K; Takenaka, R; Tsugeno, H | 1 |
| Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS | 1 |
| Howden, CW; Hunt, B; Laine, L; Leifke, E; Mulford, DJ; Sharma, P; Smith, N | 1 |
| Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S | 1 |
| Chey, WD; Howden, CW; Hunt, BJ; Laine, L; López, LJ; Mégraud, F | 1 |
| Bao, Y; Cai, L; Gu, Y; Li, X; Yang, T; Zhang, Z | 1 |
| Deguchi, H; Fernandez, J; Igarashi, A; Ishii, M; Kawai, T; Suzuki, M; Tsujita, K | 1 |
| DeVault, K; Hunt, B; Katz, P; Laine, L; Lowe, J; Mitev, S; Spechler, S | 1 |
| Ding, YM; Han, ZX; Ji, R; Li, YY; Lin, BS; Zhang, WL | 1 |
| Adler, DG; Bapaye, J; Chandan, OC; Chandan, S; Deliwala, S; Dhindsa, B; Facciorusso, A; Kassab, LL; Mohan, BP; Ramai, D | 1 |
3 review(s) available for pyrroles and lansoprazole
| Article | Year |
|---|---|
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Treatment Outcome | 2023 |
Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Topics: Esophagitis; Humans; Lansoprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2023 |
20 trial(s) available for pyrroles and lansoprazole
| Article | Year |
|---|---|
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis; Female; Gastrins; Humans; Lansoprazole; Los Angeles; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2015 |
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Topics: Adult; Aged; Cytochrome P-450 CYP2C19; Double-Blind Method; Esophagitis; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Wound Healing | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2017 |
Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the
Topics: Adult; Aged; Breath Tests; Drug Monitoring; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; Urease | 2017 |
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Single-Blind Method; Sulfonamides; Treatment Outcome | 2017 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence Trials as Topic; Female; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Pyrroles; Recurrence; Secondary Prevention; Single-Blind Method; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Japan; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Pyrroles; Recurrence; Secondary Prevention; Sulfonamides; Treatment Outcome | 2018 |
Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Humans; Lansoprazole; Male; Middle Aged; Postoperative Complications; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2018 |
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Gastric Mucosa; Gastroesophageal Reflux; Heartburn; Humans; Incidence; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Treatment Outcome | 2018 |
Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
Topics: Aged; Endoscopic Mucosal Resection; Female; Hematemesis; Hemoglobins; Humans; Lansoprazole; Male; Melena; Middle Aged; Postoperative Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2019 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Topics: Adult; Aged; Double-Blind Method; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2019 |
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Severity of Illness Index; Sulfonamides; Treatment Outcome; Wound Healing | 2020 |
Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial.
Topics: Dissection; Endoscopic Mucosal Resection; Humans; Lansoprazole; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2021 |
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects.
Topics: Adult; Humans; Hydrogen-Ion Concentration; Lansoprazole; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Neoplasm Recurrence, Local; Pyrroles; Sulfonamides | 2022 |
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; United States | 2022 |
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Topics: Adult; Esophagitis; Humans; Lansoprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2023 |
11 other study(ies) available for pyrroles and lansoprazole
| Article | Year |
|---|---|
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Dithiothreitol; Gastric Acid; Gastric Mucosa; Histamine; Hydrogen-Ion Concentration; Imidazoles; In Vitro Techniques; Kinetics; Lansoprazole; Ligation; Male; Potassium; Proton Pump Inhibitors; Pylorus; Pyrroles; Rats; Rats, Sprague-Dawley; Stomach; Sulfonamides; Swine | 2010 |
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cells, Cultured; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Potassium; Proton Pump Inhibitors; Pyrroles; Rabbits; Stomach; Sulfonamides | 2011 |
A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cimetidine; Dogs; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Histamine; Histamine Agonists; Hydrogen-Ion Concentration; Lansoprazole; Male; Potassium; Proton Pump Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2011 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
Effects of vonoprazan on intractable non-steroidal anti-inflammatory drug-induced ulcers that cannot be controlled with conventional proton pump inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Lansoprazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Stomach Ulcer; Sulfonamides | 2017 |
Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.
Topics: Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Humans; Japan; Lansoprazole; Logistic Models; Middle Aged; Multivariate Analysis; Postoperative Complications; Potassium; Propensity Score; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2018 |
Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy.
Topics: Adult; Aged; Ambulatory Care Facilities; Cost-Benefit Analysis; Drug Costs; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Pharmacists; Proton Pump Inhibitors; Pyrroles; Quality of Life; Sulfonamides; Treatment Outcome | 2019 |
Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Topics: Adult; Cost-Benefit Analysis; Drug Administration Schedule; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Japan; Lansoprazole; Markov Chains; Pyrroles; Quality of Life; Sulfonamides | 2019 |
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Erythema Multiforme; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sex Factors; Stevens-Johnson Syndrome; Sulfonamides | 2020 |
Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
Topics: Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Esophagitis, Peptic; Genotype; Humans; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Esomeprazole; Gastrointestinal Hemorrhage; Humans; Japan; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Secondary Prevention | 2023 |